| scholarly article | Q13442814 |
| P2093 | author name string | Giuseppe Novelli | |
| Emiliano Giardina | |||
| Raffaella Cascella | |||
| Stefania Zampatti | |||
| Antonella Pirazzoli | |||
| Laura Stocchi | |||
| P2860 | cites work | PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events | Q80397260 |
| HLA-B*5701 typing: evaluation of an allele-specific polymerase chain reaction melting assay | Q80456842 | ||
| A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome | Q83143933 | ||
| New allele frequency database: http://www.allelefrequencies.net | Q28204761 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir | Q33956146 | ||
| Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease | Q34007172 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity | Q34332730 | ||
| Drug hypersensitivity in HIV. | Q34647952 | ||
| A chromatic explosion: the development and future of multiparameter flow cytometry. | Q34919897 | ||
| Genomic and personalized medicine: foundations and applications | Q35014059 | ||
| The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. | Q37111658 | ||
| High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients | Q37150304 | ||
| Successful translation of pharmacogenetics into the clinic: the abacavir example | Q37436365 | ||
| HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects | Q37514235 | ||
| Multiparameter analysis of human lymphocyte subpopulations using flow cytometry | Q39478041 | ||
| Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture | Q39478345 | ||
| HLA-B locus sequence-based typing | Q40817594 | ||
| A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01. | Q42868757 | ||
| An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe | Q43106626 | ||
| Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity | Q43532377 | ||
| Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity | Q43734275 | ||
| Individualising HIV treatment--pharmacogenetics and immunogenetics | Q43913157 | ||
| Abacavir hypersensitivity reaction | Q43933908 | ||
| Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. | Q44393316 | ||
| HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing | Q46492432 | ||
| External quality assessment of HLA-B*5701 reporting: an international multicentre survey | Q46895930 | ||
| Large-scale oligonucleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly accurate, specific, and reliable | Q72337473 | ||
| HLA-B*5701 screening for susceptibility to abacavir hypersensitivity | Q79818203 | ||
| P433 | issue | 4 | |
| P921 | main subject | abacavir | Q304330 |
| biomarker | Q864574 | ||
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 314-320 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Current Genomics | Q5195047 |
| P1476 | title | The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods | |
| P478 | volume | 13 |
| Q35889793 | Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. |
| Q41078615 | Comparative analysis between saliva and buccal swabs as source of DNA: lesson from HLA-B*57:01 testing. |
| Q28546416 | Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care |
| Q30758299 | Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data |
| Q41747771 | Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01. |
| Q44558289 | External quality assessment of patient HLA-B*57:01 testing prior to abacavir prescription |
| Q43453078 | Frequencies of immune hypersensitivity reaction-associated HLA class I alleles in healthy South African Indian and mixed ancestry populations determined by a novel real-time PCR assay. |
| Q35045019 | Full-length novel MHC class I allele discovery by next-generation sequencing: two platforms are better than one |
| Q47553722 | HLA Association with Drug-Induced Adverse Reactions. |
| Q33819062 | PharmGKB summary: abacavir pathway |
| Q38391340 | Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice |
| Q38857254 | Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis. |
| Q58827221 | The Collaborative African Genomics Network (CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV and HIV-tuberculosis infection in sub-Saharan Africa |
| Q58827223 | The Collaborative African Genomics Network (CAfGEN): Applying Genomic technologies to probe host factors important to the progression of HIV and HIV-tuberculosis infection in sub-Saharan Africa |
Search more.